95 related articles for article (PubMed ID: 21072048)
1. Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients.
Nicolas E; Ramus C; Berthier S; Arlotto M; Bouamrani A; Lefebvre C; Morel F; Garin J; Ifrah N; Berger F; Cahn JY; Mossuz P
Leukemia; 2011 Jan; 25(1):57-65. PubMed ID: 21072048
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses.
Braoudaki M; Tzortzatou-Stathopoulou F; Anagnostopoulos AK; Papathanassiou C; Vougas K; Karamolegou K; Tsangaris GT
Amino Acids; 2011 Mar; 40(3):943-51. PubMed ID: 20711619
[TBL] [Abstract][Full Text] [Related]
3. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis.
Graf M; Reif S; Kröll T; Hecht K; Nuessler V; Schmetzer H
Am J Hematol; 2006 Apr; 81(4):227-35. PubMed ID: 16550517
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
[TBL] [Abstract][Full Text] [Related]
5. [Proteomics analysis of bone marrow cells of acute myeloid leukemia M2a and prognostic significance thereof].
Tian S; Meng FY; Tang JM
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(8):538-41. PubMed ID: 17459203
[TBL] [Abstract][Full Text] [Related]
6. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
7. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
Tourneur L; Delluc S; Lévy V; Valensi F; Radford-Weiss I; Legrand O; Vargaftig J; Boix C; Macintyre EA; Varet B; Chiocchia G; Buzyn A
Cancer Res; 2004 Nov; 64(21):8101-8. PubMed ID: 15520222
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
Kornblau SM; Thall PF; Estrov Z; Walterscheid M; Patel S; Theriault A; Keating MJ; Kantarjian H; Estey E; Andreeff M
Clin Cancer Res; 1999 Jul; 5(7):1758-66. PubMed ID: 10430080
[TBL] [Abstract][Full Text] [Related]
9. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
11. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia.
Tamm I; Richter S; Oltersdorf D; Creutzig U; Harbott J; Scholz F; Karawajew L; Ludwig WD; Wuchter C
Clin Cancer Res; 2004 Jun; 10(11):3737-44. PubMed ID: 15173080
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
13. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
[TBL] [Abstract][Full Text] [Related]
14. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival.
Tzankov A; Strasser U; Dirnhofer S; Menter T; Arber C; Jotterand M; Rovo A; Tichelli A; Stauder R; Günthert U
Ann Hematol; 2011 Aug; 90(8):901-9. PubMed ID: 21274712
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets.
López-Pedrera C; Villalba JM; Siendones E; Barbarroja N; Gómez-Díaz C; Rodríguez-Ariza A; Buendía P; Torres A; Velasco F
Proteomics; 2006 Apr; 6 Suppl 1():S293-9. PubMed ID: 16521150
[TBL] [Abstract][Full Text] [Related]
16. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
17. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
[TBL] [Abstract][Full Text] [Related]
18. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
19. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
20. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
